Why the study?
Does cilostazol improve syncope and sinus arrest in a patient with sick sinus syndrome?
Does cilostazol improve syncope and sinus arrest in a patient with sick sinus syndrome?
Cilostazol may be a useful pharmacological option for treating syncope attacks due to sick sinus syndrome, though long-term effects require further study.
May support cilostazol in refractory sick sinus syndrome syncope; hypothesis-generating case report requiring prospective trials.
In this case report we describe an 80-year-old man with sick sinus syndrome (SSS) who developed syncope attacks. The diagnosis of SSS was based on electrocardiographic evidence of markedly prolonged sinus arrests associated with syncope attacks while in hospital. The patient was given cilostazol, an antithrombotic agent that selectively inhibits cyclic nucleotide phosphodiesterase type 3, at a dose of 100 mg twice daily. The syncope attacks ceased, and an electrocardiogram obtained 1 week after the start of cilostazol administration showed no evidence of sinus arrest. The outcome of this case suggests that cilostazol may be useful in patients with syncope attacks due to SSS, although the long-term chronotropic effects of cilostazol need to be evaluated.
No takes yet. Share an insight, caveat, or question.
Moriya et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: